New York, USA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- DURYSTA’s Market Potential Across the 7MM is Set to Soar During the Study Period (2020–2034) as a Game-Changer in Ophthalmic Care | DelveInsight The ...
- DURYSTA™ lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30 percent from baseline in two Phase 3 studies - - Allergan continues five ongoing ...
Please provide your email address to receive an email when new articles are posted on . The recent paradigm shift in the treatment of glaucoma moving toward earlier intervention, better managing ...
Please provide your email address to receive an email when new articles are posted on . WAIKOLOA, Hawaii — At Hawaiian Eye 2022, I. Paul Singh, MD, discusses some of the advantages of the use of ...
(MENAFN- GlobeNewsWire - Nasdaq) The DURYSTA market potential seems strong due to the increasing prevalence of glaucoma, the need for long-term, non-adherence-dependent treatments, and its advantage ...
DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results